AGM Information • Jul 23, 2020
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 9216T
ValiRx PLC
23 July 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Result of AGM
ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The proxy votes are set out below:-
| Resolutions | For | Against | Discretion |
| Resolution 1 - Receive the annual report and accounts | 4,612,178 | 0 | 2,000 |
| Resolution 2 - Re-appoint Gerry Desler as a director | 4,226,311 | 377,739 | 2,000 |
| Resolution 3 - Re-appoint Dr Suzanne Dilly as a director | 4,579,542 | 23,437 | 2,000 |
| Resolution 4 - Re-appoint Martin Lampshire as a director | 4,579,542 | 24,623 | 2,000 |
| Resolution 5 - Re-appoint Dr Kevin Cox as a director | 4,580,958 | 23,207 | 2,000 |
| Resolution 6 - Re-appoint the auditors | 4,573,342 | 26,058 | 2,000 |
| Resolution 7 - Set the auditors' remuneration | 4,548,033 | 49,943 | 2,000 |
| Resolution 8 - Provide authority to allot share capital | 4,441,339 | 62,857 | 2,008 |
| Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution) | 4,436,339 | 67,857 | 2,008 |
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
| ValiRx plc | Tel: +44 (0) 20 7073 2628 www.valirx.com |
| Suzanne Dilly | [email protected] |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
| Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker |
Tel: +44 (0) 20 7469 0930 |
Notes for Editors
About ValiRx
ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
RAGSEDFFDESSEIW
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.